RAINBOW: A GLOBAL, PHASE 3, DOUBLE-BLIND STUDY OF RAMUCIRUMAB (RAM) PLUS PACLITAXEL (PTX) VERSUS PLACEBO (PL) plus PTX IN THE TREATMENT OF ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA FOLLOWING DISEASE PROGRESSION ON FIRST-LINE PLATINUM- AND FLUOROPYRIMIDINE-CONTAINING COMBINATION THERAPY: A SUBGROUP ANALYSIS OF WESTERN POPULATION

被引：0

作者：

Wilke, Hansjochen ^{[1
]}

Clingan, Philip ^{[2
]}

Ananda, Sumi ^{[3
]}

Kurteva, Galina ^{[4
]}

Suuroja, Tiit ^{[5
]}

Folprecht, Gunnar ^{[6
]}

Beny, Alexander ^{[7
]}

Pastorelli, Davide ^{[8
]}

Cesas, Alvydas ^{[9
]}

Nowecki, Zbigniew ^{[10
]}

Toganel, Cornelia ^{[11
]}

Bodoky, Gyoergy ^{[12
]}

Lipatov, Oleg ^{[13
]}

Miron, Maria Limon ^{[14
]}

Cunningham, David ^{[15
]}

Cummins, Sebastian ^{[16
]}

Wainberg, Zev ^{[17
]}

Ko, Andrew ^{[18
]}

Emig, Michael ^{[19
]}

Chandrawansa, Kumari ^{[20
]}

van Cutsem, Eric ^{[21
]}

机构：

[1] Kliniken Essen Mitte, Essen, Germany

[2] Southern Med Day Care Ctr, Wollongong, NSW, Australia

[3] Western Hlth, Melbourne, Vic, Australia

[4] Specialised Hosp Act Treatment Oncol, Sofia, Bulgaria

[5] North Estonia Med Ctr, Tallinn, Estonia

[6] Univ Klinikum Carl Gustav Carus, Dresden, Germany

[7] Rambam Hlth Care Campus, Haifa, Israel

[8] Ist Oncol Veneto IRCCS, Padua, Italy

[9] Klaipeda Univ Hosp, Klaipeda, Lithuania

[10] Ctr Onkol Inst M Sklodowskiej Curie, Warsaw, Poland

[11] Spitalul Clin Judetean Mures, Targu Mures, Romania

[12] St Laszlo Hosp, Dept Oncol, Budapest, Hungary

[13] Republican Clin Oncol Dispensary, Ufa, Russia

[14] HUV Rocio, Seville, Spain

[15] Royal Marsden Hosp, London SW3 6JJ, England

[16] Royal Surrey Cty Hosp, Guildford, Surrey, England

[17] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA

[18] Univ Calif San Francisco, San Francisco, CA 94143 USA

[19] Eli Lilly & Co, Homburg, Germany

[20] Eli Lilly & Co, Indianapolis, IN 46285 USA

[21] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 10卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

362

引用

页码：171 / 171

页数：1

共 44 条

[21] Age subgroup analysis of efficacy and safety data from two phase 3 studies of second-line ramucirumab (RAM) versus placebo (PL) in patients (pts) with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINBOW and REGARD)
Cascinu, S.
Aprile, G.
Pastorelli, D.
Pinto, C.
Bordonaro, R.
Farina, G.
Amoroso, D.
Bilancia, D.
Ciuffreda, L.
Sartori, D.
Falcone, A.
Silvestris, N.
Beretta, G. D.
Buonadonna, A.
Sobrero, A.
Tamburini, E.
Amoroso, V.
Hsu, Y.
Chandrawansa, K.
Wilke, H.
Fuchs, C.
Passalacqua, R.
ANNALS OF ONCOLOGY, 2015, 26 : 90 - 90
[22] KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma
Tabernero, J.
Bang, Y.
Van Cutsem, E.
Fuchs, C.
Janjigian, Y.
Bhagia, P.
Li, K.
Adelberg, D.
Qin, S.
ANNALS OF ONCOLOGY, 2020, 31 : S101 - S102
[23] A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Qin, S.
Tabernero, J.
van Cutsem, E.
Fuchs, C. S.
Janjigian, Y. Y.
Bhagia, P.
Li, K.
Adelberg, D.
Bang, Y-J.
ANNALS OF ONCOLOGY, 2020, 31 : S1316 - S1317
[24] Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised multicentre, double-blind, phase 3 trial
Xu, Rui-Hua
Zhang, Yanqiao
Pan, Hongming
Feng, Jifeng
Zhang, Tao
Liu, Tianshu
Qin, Yanru
Qin, Shukui
Yin, Xianli
Liu, Baorui
Ba, Yi
Yang, Nong
Voon, Pei Jye
Tanasanvimon, Suebpong
Zhou, Chan
Li Zhang, Wan
Shen, Lin
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (12): : 1015 - 1024
[25] Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study
Valle, Juan W.
Bai, Li-Yuan
Orlova, Rashida
Van Cutsem, Eric
Alfonso, Jorge Adeva
Chen, Li-Tzong
Obermannova, Radka
Ettrich, Thomas Jens
Chen, Jen-Shi
Wasan, Harpreet Singh
Denlinger, Crystal S.
Vogel, Arndt
He, Aiwu Ruth
Bousmans, Nathalie
Girvan, Allicia C.
Zhang, Wei
Walgren, Richard A.
Carlesi, Roberto
Oh, Do-Youn
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[26] Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer
Chau, I.
Al-Batran, S-E.
Luft, A.
Kowalyszyn, R. D.
Hernandez, C. A.
Pfeiffer, P.
Wojcik, E.
Bodoky, G.
Madi, A.
Brenner, B.
De Vita, F.
Folprecht, G.
Peltola, K.
Lorenzen, S.
Denlinger, C.
Liepa, A.
Das, M.
Wei, R.
Fuchs, C. S.
ANNALS OF ONCOLOGY, 2018, 29
[27] Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
Van Cutsem, E.
Obermannova, R.
Bodoky, G.
Prausova, J.
Garcia-Carbonero, R.
Ciuleanu, T.
Garcia Alfonso, P.
Portnoy, D.
Cohn, A.
Yamazaki, K.
Clingan, P.
Yoshino, T.
Polikoff, J.
Lonardi, S.
Macarulla, T.
Yang, L.
Nasroulah, F.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S365 - S365
[28] REGARD phase III, randon ed, double-blinded trial of mum ib and best supportive care (BSC) versus placebo and BSC in the Ireattneiti of metasta lie gastric or gastroesophageal junction (GEJ) adenocarcino u following disease progression on first-line platinum- and/or fluorop., midine-containing combination therapy.
Fuchs, Charles S.
Tomasek, Jiri
Cho, Jae Yong
Dumitru, Filip
Passalacqua, Rodolfo
Goswami, Chanchal
Safran, Howard
dos Santos, Lucas Vieira
Aprile, Giuseppe
Ferry, David R.
Melichar, Bohuslav
Tehfe, Mustapha
Topuzov, Eldar
Tabemero, Josep
Zalcberg, John Raymond
Chau, Ian
Koshiji, Minori
Hsu, Yanzhi
Schwartz, Jonathan D.
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[29] RILOMET-1: An international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Cunningham, David
Al-Batran, Salah-Eddin
Davidenko, Irina
Ilson, David H.
Murad, Andre M.
Tebbutt, Niall C.
Jiang, Yizhou
Lou, Elwyn
Dubey, Santa
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[30] A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial
Doi, Toshihiko
Kang, Yoon-Koo
Muro, Kei
Jiang, Yizhou
Jain, Rajul K.
Lizambri, Richard
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)

← 1 2 3 4 5 →